Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.
Advanced Solid Malignancies
DRUG: Tiragolumab|DRUG: Atezolizumab|RADIATION: Radiation Therapy
Safety and Adverse Events (AEs), Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year
Primary Objectives:

1. To evaluate the safety of tiragolumab + atezolizumab + RadScopal™ XRT (Phase I).
2. To evaluate the efficacy of tiragolumab + atezolizumab + RadScopal™ XRT (Phase Ib).

Secondary Objectives:

1. To compare the efficacy of tiragolumab + atezolizumab + RadScopal™ XRT to tiragolumab + atezolizumab and atezolizumab + RadScopal™ XRT.
2. To evaluate time-to-event outcomes of tiragolumab + atezolizumab + RadScopal™ XRT.